Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Risk stratification with nomograms improves decision-making in localized sarcoma

Javier Martin-Broto, MD, PhD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, emphasizes the utility of nomograms in risk stratification for sarcoma patients with localized disease, particularly those with limb and trunk wall, and retroperitoneal tumors. Dr Martin-Broto notes that the nomogram is the most validated and personalized tool for predicting the risk of recurrence and mortality, and that a threshold of 40% risk of death by sarcoma at 10 years is commonly used to guide perioperative chemotherapy recommendations for patients with high-risk subtypes such as UPS, synovial sarcoma, and myxoid liposarcoma. This approach is particularly relevant for patients with these subtypes, which represent 80% of primary sarcoma tumors in limbs or trunk.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.